JAK2 and essential thrombocythemia: In this context, the discovery of calreticulin (CARL) mutations occurring in JAK2- and MPL-negative essential thrombocythemia (ET) and primary myelofibrosis (PMF)17, 18 facilitated diagnostic precision and may also harbor prognostic relevance.19